Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Nursing Assessment of the Genitourinary System I: Health History01:21

Nursing Assessment of the Genitourinary System I: Health History

The genitourinary system is critical to maintaining fluid balance, waste elimination, and reproductive function. Nurses play a vital role in assessing this system, beginning with a thorough health history. This process involves gathering patient information, identifying risk factors, and recognizing symptoms of genitourinary disorders. Early detection is vital for timely interventions and management.1. Gathering Patient InformationA complete health history includes the patient’s personal,...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Nonpharmacological and Nonsurgical Intervention for Lower Urinary Tract Symptoms in Parkinson's Disease: A Systematic Review and Meta-analysis.

European urology open science·2026
Same author

Urogenital dysfunction in neurological diseases.

Nature reviews. Neurology·2026
Same author

Subgroups of lower urinary tract symptoms in men and their association with patient-centered outcomes: a cluster analysis of the 2023 Japan community health survey.

World journal of urology·2026
Same author

Diagnostic Utility of Fractional Anisotropy and the Apparent Diffusion Coefficient in the Median Nerve: A Nerve Conduction Velocity-Stratified Evaluation Using 3T MRI.

Cureus·2025
Same author

Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co-Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder.

Lower urinary tract symptoms·2025
Same author

Unsupervised machine learning approach to interpret complex lower urinary tract symptoms and their impact on quality of life in adult women.

World journal of urology·2025

Related Experiment Video

Updated: Jun 17, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Genitourinary dysfunction in Parkinson's disease.

Ryuji Sakakibara1, Tomoyuki Uchiyama, Tomonori Yamanishi

  • 1Neurology Division, Department of Internal Medicine, Sakura Medical Center, Toho University, Shimoshizu, Sakura 285-8741, Japan. sakakibara@sakura.med.toho-u.ac.jp

Movement Disorders : Official Journal of the Movement Disorder Society
|January 16, 2010
PubMed
Summary

Nonmotor symptoms like bladder and sexual dysfunction are common in Parkinson's disease (PD). Treatments focus on managing symptoms, as they often don't respond to standard Parkinson's medications.

More Related Videos

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

Related Experiment Videos

Last Updated: Jun 17, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

Area of Science:

  • Neurology
  • Urology
  • Sexual Medicine

Background:

  • Bladder and sexual dysfunction are prevalent nonmotor symptoms in Parkinson's disease (PD).
  • These genitourinary issues are frequently unresponsive to levodopa, unlike motor symptoms.
  • Understanding the distinct pathophysiology may aid in differentiating PD from other neurological disorders like multiple system atrophy.

Purpose of the Study:

  • To elucidate the distinct neurobiological underpinnings of bladder and sexual dysfunction in Parkinson's disease.
  • To highlight the differential response of these nonmotor symptoms to established treatments.
  • To emphasize the potential role of understanding pathophysiology in differential diagnosis.

Main Methods:

  • Review of current literature on the neuroanatomy and neurochemistry of bladder and sexual function in PD.
  • Analysis of the dopaminergic pathways involved in the basal ganglia and hypothalamus.
  • Comparison of the pathophysiological mechanisms in PD versus multiple system atrophy.

Main Results:

  • Bladder overactivity in PD is linked to altered dopamine-basal ganglia circuits suppressing the micturition reflex.
  • Sexual dysfunction in PD stems primarily from hypothalamic dysfunction affecting dopamine-oxytocin pathways.
  • Genitourinary dysfunction pathophysiology in PD is distinct from multiple system atrophy.

Conclusions:

  • Bladder and sexual dysfunction in Parkinson's disease arise from distinct central nervous system pathways.
  • Current treatments include anticholinergic agents for bladder issues and phosphodiesterase inhibitors for sexual dysfunction.
  • Management strategies aim to improve patients' quality of life by addressing these nonmotor symptoms.